Preventive Effects of Amino-acid-rich Elemental Diet Elental® on Chemotherapy-induced Oral Mucositis in Patients with Colorectal Cancer: a Prospective Pilot Study

Overview

Journal Support Care Cancer

Specialties Critical Care
Oncology

Date 2015 Aug 13

PMID 26266658

Citations 15

Authors

Yutaka Ogata

Nobuya Ishibashi

Keizou Yamaguchi

Shinji Uchida

Hideki Kamei

Goichi Nakayama

Hiroaki Hirakawa

Masahiko Tanigawa

Yoshito Akagi

Affiliations

Soon will be listed here.

Abstract

Purpose: The prospective pilot study was designed to evaluate the preventive effects of amino-acid-rich elemental diet (ED), Elental(®), on chemotherapy-induced oral mucositis in patients with colorectal cancer. The factors influencing its efficacy are also investigated.

Methods: A total of 22 eligible patients with colorectal cancer experiencing grade 1-3 oral mucositis during treatment with fluorouracil-based chemotherapy entered the current study. Their average age was 67 years. There were 10 male and 12 female. The PS was 0 in the majority of patients. Patients received two courses of the same chemotherapy regimen and Elental(®) concurrently after recovery to grade 0 or 1 oral mucositis.

Results: FOLFOX6 + bevacizumab in 8 patients, FOLFIRI + bevacizumab in 8 patients, FOLFIRI + panitumumab in 1 patient, FOLFIRI in 1 patient, XELOX + bevacizumab in 2 patients, and S-1 + cetuximab in 2 patients were used as first-line (16 cases) or as second-line (6 cases) chemotherapy. Dose reduction of 5-fluorouracil (5-FU) or oral fluoropyrimidine was performed in the 2 patients achieving grade 3 oral mucositis and in the 3 patients achieving grade 2 oral mucositis. The maximum grade of oral mucositis decreased in 18 of the 22 patients during the first treatment course with Elental(®) (p = 0.0002) and in 20 of the 22 patients in the second course (p < 0.0001). Multivariate analyses found that the dose reduction in 5-FU or oral fluoropyrimidine, ED intake, and the prior administration of ED were each a significant factor for the preventive efficacy on oral mucositis.

Conclusion: The amino-acid-rich elemental diet Elental(®) may be useful as a countermeasure for 5-FU-based chemotherapy-induced oral mucositis in patients with colorectal cancer.

Citing Articles

Impact of a glutamine-enriched peptide formula on gastrointestinal toxicity and on the interruption of oncologic treatment in patients with adenocarcinoma of the rectum.

Salas-Salas B, Ferrera-Alayon L, Calleja-Fernandez A, Chicas-Sett R, Nogues-Ramia E, Zafra-Martin J Front Nutr. 2025; 11:1414367.

PMID: 39758311 PMC: 11697424. DOI: 10.3389/fnut.2024.1414367.

Nutritional Intervention for the Elderly during Chemotherapy: A Systematic Review.

Vella R, Pizzocaro E, Bannone E, Gualtieri P, Frank G, Giardino A Cancers (Basel). 2024; 16(16).

PMID: 39199582 PMC: 11352472. DOI: 10.3390/cancers16162809.

A Free Amino Acid Diet Alleviates Colorectal Tumorigenesis through Modulating Gut Microbiota and Metabolites.

Yu Y, Li G, Ren Y, Xu X, Xu Z, Geng Y Nutrients. 2024; 16(7).

PMID: 38613073 PMC: 11013359. DOI: 10.3390/nu16071040.

A Narrative Review about Nutritional Management and Prevention of Oral Mucositis in Haematology and Oncology Cancer Patients Undergoing Antineoplastic Treatments.

Garcia-Gozalbo B, Cabanas-Alite L Nutrients. 2021; 13(11).

PMID: 34836330 PMC: 8618139. DOI: 10.3390/nu13114075.

Preoperative Elemental Diet before Laparoscopic Anterior Resection in Patients with Advanced Stenotic Rectal Cancer.

Yoshida T, Homma S, Ichikawa N, Iijima H, Taketomi A J Anus Rectum Colon. 2021; 5(4):395-404.

PMID: 34746504 PMC: 8553358. DOI: 10.23922/jarc.2021-026.

References

Vermeulen M, van de Poll M, Ligthart-Melis G, Dejong C, van den Tol M, Boelens P . Specific amino acids in the critically ill patient--exogenous glutamine/arginine: a common denominator?. Crit Care Med. 2007; 35(9 Suppl):S568-76. DOI: 10.1097/01.CCM.0000278600.14265.95. View

Sornsuvit C, Komindr S, Chuncharunee S, Wanikiat P, Archararit N, Santanirand P . Pilot Study: effects of parenteral glutamine dipeptide supplementation on neutrophil functions and prevention of chemotherapy-induced side-effects in acute myeloid leukaemia patients. J Int Med Res. 2008; 36(6):1383-91. DOI: 10.1177/147323000803600628. View

Choi K, Lee S, Oh S, Lim S, Lim S, Jeon W . The effect of oral glutamine on 5-fluorouracil/leucovorin-induced mucositis/stomatitis assessed by intestinal permeability test. Clin Nutr. 2006; 26(1):57-62. DOI: 10.1016/j.clnu.2006.07.003. View

Stiff P, Erder H, Bensinger W, Emmanouilides C, Gentile T, Isitt J . Reliability and validity of a patient self-administered daily questionnaire to assess impact of oral mucositis (OM) on pain and daily functioning in patients undergoing autologous hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2006; 37(4):393-401. DOI: 10.1038/sj.bmt.1705250. View

Keefe D, Schubert M, Elting L, Sonis S, Epstein J, Raber-Durlacher J . Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109(5):820-31. DOI: 10.1002/cncr.22484. View

Cory J, Cory A . Critical roles of glutamine as nitrogen donors in purine and pyrimidine nucleotide synthesis: asparaginase treatment in childhood acute lymphoblastic leukemia. In Vivo. 2006; 20(5):587-9. View

Barasch A, Peterson D . Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003; 39(2):91-100. DOI: 10.1016/s1368-8375(02)00033-7. View

Rosen L, Abdi E, Davis I, Gutheil J, Schnell F, Zalcberg J . Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol. 2006; 24(33):5194-200. DOI: 10.1200/JCO.2005.04.1152. View

Blijlevens N, Donnelly J, Naber A, Schattenberg A, DePauw B . A randomised, double-blinded, placebo-controlled, pilot study of parenteral glutamine for allogeneic stem cell transplant patients. Support Care Cancer. 2005; 13(10):790-6. DOI: 10.1007/s00520-005-0790-y. View

10.

Gaurav K, Goel R, Shukla M, Pandey M . Glutamine: A novel approach to chemotherapy-induced toxicity. Indian J Med Paediatr Oncol. 2012; 33(1):13-20. PMC: 3385273. DOI: 10.4103/0971-5851.96962. View

11.

Goto A, Yamada Y, Yasui H, Kato K, Hamaguchi T, Muro K . Phase II study of combination therapy with S-1 and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 2006; 17(6):968-73. DOI: 10.1093/annonc/mdl066. View

12.

Peterson D, Jones J, Petit 2nd R . Randomized, placebo-controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline-based chemotherapy. Cancer. 2006; 109(2):322-31. DOI: 10.1002/cncr.22384. View

13.

Noe J . L-glutamine use in the treatment and prevention of mucositis and cachexia: a naturopathic perspective. Integr Cancer Ther. 2009; 8(4):409-15. DOI: 10.1177/1534735409348865. View

14.

Raber-Durlacher J, von Bultzingslowen I, Logan R, Bowen J, Al-Azri A, Everaus H . Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer. 2012; 21(1):343-55. DOI: 10.1007/s00520-012-1594-5. View

15.

Sonis S, Elting L, Keefe D, Peterson D, Schubert M, Hauer-Jensen M . Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100(9 Suppl):1995-2025. DOI: 10.1002/cncr.20162. View

16.

Douillard J, Cunningham D, Roth A, Navarro M, James R, Karasek P . Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000; 355(9209):1041-7. DOI: 10.1016/s0140-6736(00)02034-1. View

17.

Chattopadhyay S, Saha A, Azam M, Mukherjee A, Sur P . Role of oral glutamine in alleviation and prevention of radiation-induced oral mucositis: A prospective randomized study. South Asian J Cancer. 2014; 3(1):8-12. PMC: 3961877. DOI: 10.4103/2278-330X.126501. View

18.

Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T . XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004; 22(11):2084-91. DOI: 10.1200/JCO.2004.11.069. View

19.

Sonis S . Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol. 2007; 5(9 Suppl 4):3-11. View

20.

Skubitz K, Anderson P . Oral glutamine to prevent chemotherapy induced stomatitis: a pilot study. J Lab Clin Med. 1996; 127(2):223-8. DOI: 10.1016/s0022-2143(96)90082-7. View